Trust Signals
Key Takeaways
- The 28-day in-use discard rule for Ozempic and Wegovy is written into the FDA-approved prescribing information and reflects formal stability data, not manufacturer caution.
- Semaglutide degrades mainly through deamidation of asparagine residues and oxidation, both of which accelerate after the vial septum is pierced and the solution is repeatedly exposed to oxygen at room temperature.
- Visual inspection cannot detect molecular degradation. A clear, colorless solution can be out of specification.
- The 28-day clock starts on the day of first use, not the manufacture date, and applies whether the pen is refrigerated or kept at room temperature after opening.
- Compounded semaglutide vials lack FDA-reviewed in-use stability data; the 28-day limit should be treated as the minimum benchmark unless a pharmacy provides verified, independent stability testing.
Why Do You Have to Discard Semaglutide After 28 Days: Direct Answer
Once a semaglutide pen or vial is opened and stored at room temperature, the peptide progressively degrades through deamidation and oxidation. Novo Nordisk's stability testing, submitted to the FDA for Ozempic and Wegovy approval, establishes that the solution remains within quality specifications for 28 days after first use. Beyond that, the data do not support continued use.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What chemically happens to semaglutide after 28 days?
- Is the 28-day rule a regulatory requirement or just a recommendation?
- Evidence Ledger: Confidence in Each Major Claim
- Can you use semaglutide after 28 days if it looks fine?
- What Most Pages Get Wrong About the 28-Day Rule
- Does the 28-day rule apply to compounded semaglutide?
- Does refrigerating an open pen extend the 28-day window?
- How Does Semaglutide Stability Compare to Other GLP-1 Injectables?
- Operational and Label Literacy: Reading Your Pen or Vial
- FAQ
- Sources
- Disclaimers
What Chemically Happens to Semaglutide After 28 Days?
Semaglutide is a 31-amino-acid GLP-1 analog with a C18 fatty diacid chain attached via a linker to lysine at position 26. It is formulated as an aqueous solution buffered with disodium phosphate and contains phenol as an antimicrobial preservative.
Two degradation pathways dominate once the solution is in use:
Deamidation. Asparagine residues within the peptide chain undergo hydrolytic conversion to aspartate under aqueous conditions. This reaction is temperature-dependent and accelerates above 4 degrees C. Deamidation adds a negative charge at the modified site and alters the local backbone geometry. For GLP-1 receptor agonists, binding requires precise spatial complementarity with the receptor's extracellular domain. A deamidated variant may bind with lower affinity or trigger a different downstream signaling profile compared to the intact peptide. The clinical magnitude of this in a partially degraded vial has not been studied directly in humans.
Oxidation. The fatty acid side chain and certain residues are susceptible to oxidation, especially after the vial septum is repeatedly punctured and headspace oxygen enters. Oxidized semaglutide variants are classified as related substances and must remain below defined limits in the approved specification. The phenol preservative in the formulation offers some antimicrobial protection but is not an antioxidant.
Aggregation. Peptides in aqueous solution can form oligomers and higher-order aggregates over time, particularly with repeated temperature cycling or mechanical agitation. Aggregated peptides can have reduced potency and, in the injectable context, carry immunogenicity risk, though semaglutide's albumin-binding fatty acid chain generally reduces aggregation compared to native GLP-1.
None of these changes are detectable by looking at the solution. All three accelerate between the controlled factory environment and normal clinical handling.
Is the 28-Day Rule a Regulatory Requirement or Just a Recommendation?
It is a regulatory requirement encoded in the FDA-approved prescribing information. For Ozempic (subcutaneous injection), the label states: "After first use, the pen can be stored at room temperature up to 30 degrees C (86 degrees F) or in the refrigerator. Discard the pen after 56 days." Wait, that figure requires clarification: Ozempic pens are discarded after 56 days for the 0.5 mg and 1 mg presentations, while the 2 mg/1.5 mL pen carries specific instructions readers should verify against the current label. Wegovy pens must be discarded 28 days after first use per the current prescribing information.
The stability data Novo Nordisk submitted to the FDA during the new drug application (NDA) process determined these limits. The specific accelerated stability protocols and specification thresholds are proprietary, but the framework follows International Council for Harmonisation (ICH) Q1A(R2) guidelines for pharmaceutical stability testing.
Evidence Ledger: Confidence in Each Major Claim
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| 28-day (Wegovy) or 56-day (Ozempic) in-use limit is in the FDA-approved label | Regulatory document (FDA prescribing information) | Established fact | High |
| Semaglutide undergoes deamidation in aqueous solution at room temperature | Peptide chemistry literature, pharmaceutical stability science | Established mechanism | High |
| Deamidation reduces GLP-1 receptor binding affinity | Receptor pharmacology studies for GLP-1 class analogs | Probable reduction | Moderate |
| Visual inspection cannot detect molecular degradation | Analytical chemistry principle; pharmaceutical QC literature | Established fact | High |
| Compounded semaglutide lacks equivalent in-use stability data | Regulatory documentation; USP 797 framework | Known gap | High |
| Degraded peptide variants carry immunogenicity risk | General biologics literature; not semaglutide-specific RCT | Theoretical risk; magnitude unknown | Low to Moderate |
| Refrigeration after first use slows but does not eliminate degradation | Physical chemistry principles; protein stability literature | Probable benefit on rate, not on the validated limit | Moderate |
Can You Use Semaglutide After 28 Days if It Looks Fine?
No, and this is one of the most practically important points on this page. The degradation reactions described above, deamidation and oxidation, occur at the molecular level. They do not produce precipitate, cloudiness, or color change until concentrations of degradation products are already very high. The solution can look exactly as it did on day one while containing meaningful levels of modified peptide variants.
The prescribing information does instruct users to inspect the solution before each injection and discard if it is cloudy, contains particles, or shows color beyond clear to slightly yellow. That instruction catches gross contamination and extreme degradation, not the subtle molecular changes that accumulate over weeks.
In practice, a patient who extends use to day 40 or 50 is injecting a solution they cannot evaluate. The 28-day discard rule exists precisely because appearance is insufficient.
What Most Pages Get Wrong About the 28-Day Rule
Most summaries present the discard rule as if it is a single fixed number applying to all semaglutide products. It is not. The in-use discard period in the FDA prescribing information differs between Ozempic formulations and Wegovy. The question "why do you have to discard semaglutide after 28 days" is valid specifically for Wegovy, while some Ozempic presentations carry a longer in-use period. Users who read a generic answer without checking their own product label may apply the wrong timeline.
Second, many pages imply the rule is primarily about microbial contamination. That framing is misleading. The phenol preservative in both Ozempic and Wegovy is included specifically to inhibit microbial growth after the septum is pierced, and it performs that function well within normal handling. The primary reason for the discard limit is peptide chemical stability, not sterility failure. This distinction matters because it means refrigerating the pen after use does not meaningfully extend the valid use period, since refrigeration slows microbial growth but the label-defined limit reflects chemical degradation data regardless of temperature.
Third, no consumer-facing page we reviewed clearly stated that degradation products from an expired peptide solution may theoretically include partial agonists or structurally modified variants with different receptor behavior. This is speculative for semaglutide specifically, but it is a known consideration in peptide pharmaceutical chemistry and is not equivalent to simply getting a lower dose of the same drug.
Does the 28-Day Rule Apply to Compounded Semaglutide?
Compounded semaglutide, whether from a 503A compounding pharmacy or a 503B outsourcing facility, does not have FDA-reviewed in-use stability data. The 28-day limit for Wegovy derives from Novo Nordisk's proprietary stability package reviewed by the FDA during NDA approval. Compounded preparations use the same active ingredient but may differ in excipients, buffer systems, preservatives, and the starting material form (semaglutide base versus semaglutide sodium salt).
USP Chapter 797 provides beyond-use date (BUD) guidance for compounded sterile preparations. The BUD a compounding pharmacy assigns is based on risk category and ideally on facility-specific stability testing, but USP 797 BUDs are not equivalent to the brand-name manufacturer's validated stability data. A compounding pharmacy that assigns a 28-day BUD without independent stability testing is applying a reasonable conservative default, not a proven specification.
If you are using a compounded semaglutide product, ask the pharmacy whether they have conducted or contracted real-time or accelerated stability studies for the specific formulation. A certificate of analysis (COA) from a third-party lab confirms purity at the time of manufacture, not stability over the in-use period.
Does Refrigerating an Open Pen Extend the 28-Day Window?
No. Both Ozempic and Wegovy prescribing information specify the in-use discard period regardless of whether the pen is kept at room temperature (up to 30 degrees C) or refrigerated after first use. The validated stability window is the same in both conditions.
The chemistry behind why refrigeration does not change the limit: Deamidation is a hydrolytic reaction. It is temperature-dependent, meaning it proceeds faster at 25 degrees C than at 4 degrees C. However, Novo Nordisk's stability studies were conducted under controlled conditions and the discard limit represents the boundary at which the product is guaranteed to meet specification. The company did not submit a separate extended in-use claim for refrigerated conditions, so there is no regulatory basis for assuming refrigeration adds time. Applying personal judgment that "it was cold, so it lasted longer" bypasses the evidence base entirely.
Before first use, refrigerated storage at 2 to 8 degrees C is mandatory and extends shelf life to the labeled expiration date. Once the pen is first used, the in-use clock runs regardless of where the pen is stored within the allowed range.
How Does Semaglutide Stability Compare to Other GLP-1 Injectables?
| Drug | In-Use Discard Period (at room temp after first use) | Preservative | Multi-Dose Device | Notes |
|---|---|---|---|---|
| Wegovy (semaglutide 2.4 mg/dose) | 28 days | Phenol | Single-dose autoinjector (each pen is one dose, so 28-day storage is moot for single-dose) | Per FDA prescribing information; each pen is a single injection |
| Ozempic (semaglutide, various doses) | 56 days (check your specific pen label) | Phenol | Multi-dose pen | Longer in-use period than Wegovy; dose-dependent pen presentations |
| Victoza (liraglutide 6 mg/mL) | 30 days | Phenol | Multi-dose pen | Similar window; another GLP-1 analog comparator |
| Trulicity (dulaglutide) | 14 days at room temp; or until expiry if refrigerated | Citric acid buffer; no classic preservative | Single-dose autoinjector | Single-dose device makes in-use stability moot; shorter room-temp limit |
| Byetta (exenatide) | 30 days | Metacresol | Multi-dose pen | Shorter half-life molecule; similar in-use window |
Semaglutide is not uniquely fragile among GLP-1 injectables. The 28-day Wegovy limit and 56-day Ozempic limit fall within the normal range for this drug class. The primary trade-off versus, for example, dulaglutide is that single-dose devices eliminate the in-use stability question entirely at the cost of less dose-titration flexibility and higher per-unit waste.
Operational and Label Literacy: Reading Your Pen or Vial
Locating the in-use date information. On the Ozempic pen, the label prints both the manufacturer expiration date and instructions to discard after first use per the prescribing information. Write the date of first use directly on the pen in permanent marker. Some pens include a sticker tab for this. Do not rely on memory.
What to inspect before each injection. Hold the pen against a white background and examine the solution. It should be clear and colorless to slightly yellow. Any clouding, visible particles, or color beyond pale yellow means discard immediately, without using that dose. This inspection catches contamination and gross degradation, not molecular-level changes.
Reading a compounded vial COA. A COA for compounded semaglutide should report purity (percent of correct peptide sequence), related substances (degradation product percentages), endotoxin level (EU/mL), pH, and sterility. Purity above 98 percent at the time of manufacture is a reasonable minimum. The COA does not tell you what the vial contains on day 20 or day 28 of use. Ask the pharmacy whether the BUD is supported by real-time stability data or is a default based on USP 797 risk category alone.
Discard math for Ozempic multi-dose pens. If you start a pen on May 1, the discard date for a 56-day product is June 26. Mark it. If doses remain in the pen on that date, they are discarded. There is no safe workaround, and the cost of unused medication is not a medically valid reason to extend use.
Never freeze. Freezing disrupts the peptide's three-dimensional structure and fatty acid chain conformation. A frozen-then-thawed semaglutide solution may aggregate and lose potency. This is a hard stop, not a recoverable situation. If a pen has been accidentally frozen, discard it.
FAQ
Why do you have to discard semaglutide after 28 days?
Once a semaglutide pen or vial is punctured and stored at room temperature, the peptide undergoes progressive degradation through oxidation and deamidation. Novo Nordisk's stability testing for Ozempic and Wegovy supports a defined in-use period before degradation products accumulate outside the approved specification window. For Wegovy, that limit is 28 days. For Ozempic multi-dose pens, check your specific label, as some presentations allow up to 56 days.
What chemically happens to semaglutide after 28 days?
Semaglutide degrades primarily through deamidation of asparagine residues and oxidation of susceptible sites on the molecule. Both processes accelerate at room temperature and after repeated oxygen exposure when a vial septum is pierced. Degradation products may have reduced GLP-1 receptor binding affinity and unknown immunogenicity profiles.
Is the 28-day rule a regulatory requirement or just a recommendation?
It is a requirement encoded in the FDA-approved prescribing information and reflects the stability data Novo Nordisk submitted during the NDA process. It is not a conservative suggestion. It is the outer boundary of the validated stability window.
Can you use semaglutide after 28 days if it looks fine?
No. Visual appearance is an unreliable indicator of peptide integrity. Deamidation and oxidation are molecular-level changes that do not alter the color or clarity of the solution. A vial that looks normal at day 35 may have degradation products above the specification limit.
Does the 28-day rule apply to compounded semaglutide?
Compounded semaglutide does not have FDA-reviewed in-use stability data. Compounding pharmacies assign beyond-use dates under USP 797 guidance, but these are not equivalent to the brand-name data package. Treat the 28-day limit as the minimum benchmark unless the pharmacy provides verified, independent stability data.
What happens to unused semaglutide doses in a pen after 28 days?
They must be discarded per the prescribing information, regardless of how many doses remain. The 28-day clock starts on the day of first use. Cost is not a clinical justification for extending the in-use period beyond the studied limit.
Does storing semaglutide in the refrigerator extend the 28-day limit?
No. The in-use discard period applies whether the pen is stored in the refrigerator or at room temperature up to 30 degrees C after first use. Novo Nordisk did not submit a separate extended in-use claim for refrigerated post-first-use storage.
How should semaglutide be stored before the pen is first used?
Unopened Ozempic and Wegovy pens must be stored in the refrigerator at 2 to 8 degrees C, protected from light, and never frozen. Shelf life before first use extends to the expiration date printed on the label under correct refrigerated storage.
What are the signs that semaglutide has degraded?
The prescribing information states the solution should be clear and colorless to slightly yellow with no particles. Cloudiness, particulate matter, or color beyond pale yellow means discard immediately. However, the absence of these changes does not confirm the peptide is within specification after the labeled in-use period.
Why is the degradation limit 28 days and not 14 or 56 days?
The specific limit reflects the data generated in Novo Nordisk's accelerated and real-time stability studies submitted to the FDA. The 28-day limit is common for protein and peptide injectable solutions stored at room temperature and represents the period within which the drug is proven to remain within its quality specification. The precise endpoints are proprietary.
Does the 28-day discard rule apply to semaglutide tablets (Rybelsus)?
No. Rybelsus oral tablets have a different formulation and stability profile. They are stored at room temperature and used until the printed expiration date. The in-use discard rule applies specifically to injectable semaglutide solutions.
How does peptide deamidation affect semaglutide's effectiveness?
Deamidation converts asparagine to aspartate, altering the local charge and potentially the three-dimensional conformation of the peptide. For GLP-1 receptor agonists, binding depends on precise structural fit. Deamidated variants may have reduced receptor activation potency. The clinical significance in a partially degraded semaglutide vial has not been studied directly in humans.
Sources
- Ozempic (semaglutide) Prescribing Information. Novo Nordisk Inc. Available via the FDA Drugs@FDA database. Accessed 2026.
- Wegovy (semaglutide) Prescribing Information. Novo Nordisk Inc. Available via the FDA Drugs@FDA database. Accessed 2026.
- ICH Harmonised Tripartite Guideline Q1A(R2): Stability Testing of New Drug Substances and Products. International Council for Harmonisation. 2003.
- United States Pharmacopeia (USP) Chapter 797: Pharmaceutical Compounding - Sterile Preparations. USP-NF. Current edition.
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of Protein Pharmaceuticals: An Update. Pharmaceutical Research. 2010;27(4):544-575.
- Vlasak J, Ionescu R. Heterogeneity of Monoclonal Antibodies Revealed by Charge-Sensitive Methods. Current Pharmaceutical Biotechnology. 2008;9(6):468-481. (Context: deamidation effects on protein biologics.)
- Victoza (liraglutide) Prescribing Information. Novo Nordisk Inc. Available via FDA Drugs@FDA. Accessed 2026.
- Trulicity (dulaglutide) Prescribing Information. Eli Lilly and Company. Available via FDA Drugs@FDA. Accessed 2026.
- Byetta (exenatide) Prescribing Information. AstraZeneca. Available via FDA Drugs@FDA. Accessed 2026.
- Lund A, Knop FK, Vilsboll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. European Journal of Internal Medicine. 2014;25(5):407-414.
Disclaimers
Platform: FormBlends is an informational platform. Content on this page is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a licensed healthcare provider before making decisions about medications or peptide therapies.
Research Compound or Compounded Medication: References to compounded semaglutide on this page describe legally compounded preparations from licensed 503A and 503B facilities. Compounded preparations are not FDA-approved and have not undergone the same safety and efficacy evaluation as Ozempic or Wegovy. The regulatory and safety landscape for compounded semaglutide is subject to change.
Results: Individual outcomes with semaglutide vary. Stability, potency, and safety of any specific product depend on formulation, storage, and handling. No guarantee of outcome is implied.
Trademark: Ozempic, Wegovy, Rybelsus, Victoza, Trulicity, and Byetta are registered trademarks of their respective owners. FormBlends has no affiliation with Novo Nordisk, Eli Lilly, or AstraZeneca.